Introduction
============

The release of cytokines into the circulation is an essential part of the inflammatory cascade that underlies sepsis. Experimental and clinical data have shown that the proinflammatory cytokine TNFα is a principal mediator of this cascade \[[@B1]-[@B3]\]. The investigational drug AZD9773, intended for intravenous infusion, contains ovine immune fragments (Fabs) of IgG that bind to human (hu)-TNFα. Here we describe the *in vitro*and *in vivo*pharmacology of AZD9773.

Methods
=======

AZD9773 binding to human TNFα was assessed using surface plasmon resonance (SPR) technology. AZD9773 functional potency was profiled versus recombinant human (r-hu)-TNFα and natural (WHO International Standard) (n)-TNFα in TNFα-mediated cytotoxicity assays using the L929 cell line. Finally, humanised mice (Tg1278/TNF^-/-^: hu-TNFα transgenic, murine TNFα null) were used to assess AZD9773 effects on endotoxin-induced serum cytokines, chemokines and related factors.

Results
=======

SPR assays revealed that r-hu-TNFα bound to immobilised AZD9773 total Fabs with an equilibrium dissociation constant (K~d~) of \~60 nM. AZD9773 neutralised both r-hu-TNFα and n-TNFα biological activity in the L929 cytotoxicity assays. AZD9773 neutralised r-hu-TNFα with an apparent inhibitory constant (K~i~) of approximately 40 pM. In humanised mice, AZD9773 produced a statistically significant reduction in 29 out of 60 serum cytokines and related factors (including hu-TNFα and murine IL-6).

Conclusions
===========

AZD9773 is a potent TNFα neutralising ovine immune Fab and, considering the modest AZD9773:TNFα binding affinity, these data indicate that there is significant synergy in neutralising TNFα bioactivity between the polyclonal anti-TNFα species that comprise AZD9773. The *in vivo*suppression of 29 out of 60 induced serum cytokines, chemokines and related factors confirms the significant role for TNFα in eliciting acute endotoxin responsiveness.
